Cardiology Department, Eastbourne General Hospital, Eastbourne, UK.
Int J Clin Pract. 2010 Jul;64(8):1062-8. doi: 10.1111/j.1742-1241.2009.02229.x.
Repeat cardioversion may be necessary in over 50% of patients with persistent atrial fibrillation (AF), but identifying responders remains challenging. This study evaluates the long-term success of direct current cardioversion (DCCV) and the clinical and echocardiographical parameters that influence them, in over 1000 sedation-cardioversion procedures undertaken at Eastbourne General Hospital between 1996 and 2006.
A total of 770 patients of mean age (SD) 70.1(10.1) underwent 1013 DCCVs (first n = 665, repeat n = 348) for atrial tachyarrhythmias from 1996 to 2006. Time to persistent arrhythmia recurrence was compared between first and multiple DCCV, and the effect of age, gender, presence of heart disease, left atrial size, fractional shortening, arrhythmia duration, anti-arrhythmic drug therapy (AAD) and other concomitant cardiac medication was evaluated using the Kaplan-Meier method and Cox's Proportional-hazards model.
In all, 33% of first and 29% of repeat DCCVs were in sinus rhythm (SR) at 12 months (m). There was no difference in median time to arrhythmia recurrence (SE) between first and multiple procedures: 1.5 +/- 0.1 m (1.3-1.7) and 1.5 +/- 0.0 m (1.4-1.6) respectively, p = 0.45. AAD use was significantly higher, arrhythmia duration shorter and more diabetic patients underwent repeat procedures. Amiodarone, OR 0.56, p = 0.04, sotalol, OR 0.61, p = 0.02 and arrhythmia duration, < 6 m, OR 0.72, p = 0.03 were independent predictors of improved outcome in first procedures only. In patients undergoing first procedures on amiodarone or sotalol, median time to arrhythmia recurrence was longer and 12 m SR rates higher, 6.0 +/- 2.4 m (42%) than those who had a repeat procedure on the same medication, 1.5 +/- 0.1 m (33%), p = 0.06.
The efficacy of first and subsequent DCCV procedures is similar, achieving a similar proportion of SR maintenance at 1 year. However, the benefits of AAD therapy are the greatest following first time procedures. Concomitant AAD therapy should be considered for all first time procedures for persistent AF.
持续性心房颤动(AF)患者中超过 50%需要重复电复律,但识别反应者仍然具有挑战性。本研究评估了 1996 年至 2006 年在伊斯特本综合医院进行的超过 1000 次镇静电复律手术中,直接电流电复律(DCCV)的长期成功率,以及影响它们的临床和超声心动图参数。
共有 770 名平均年龄(标准差)为 70.1(10.1)岁的患者接受了 1996 年至 2006 年期间用于治疗房性心动过速的 1013 次 DCCV(首次 n=665 次,重复 n=348 次)。比较首次和多次 DCCV 后持续性心律失常复发的时间,并使用 Kaplan-Meier 方法和 Cox 比例风险模型评估年龄、性别、心脏病史、左心房大小、分数缩短、心律失常持续时间、抗心律失常药物治疗(AAD)和其他伴随心脏药物的影响。
首次 DCCV 的 33%和重复 DCCV 的 29%在 12 个月(m)时处于窦性心律(SR)。首次和多次手术之间心律失常复发的中位时间(SE)无差异:分别为 1.5 +/- 0.1 m(1.3-1.7)和 1.5 +/- 0.0 m(1.4-1.6),p=0.45。AAD 的使用率明显较高,心律失常持续时间较短,更多的糖尿病患者接受重复手术。首次手术中,胺碘酮 OR 0.56,p=0.04,索他洛尔 OR 0.61,p=0.02,心律失常持续时间<6 m,OR 0.72,p=0.03 是改善预后的独立预测因素。在接受胺碘酮或索他洛尔首次手术的患者中,心律失常复发的中位时间更长,12 个月 SR 率更高,6.0 +/- 2.4 m(42%),高于接受同一药物重复手术的患者,1.5 +/- 0.1 m(33%),p=0.06。
首次和随后的 DCCV 手术的疗效相似,在 1 年内维持 SR 的比例相似。然而,AAD 治疗的益处在首次手术后最大。对于持续性 AF 的所有首次手术,应考虑同时使用 AAD 治疗。